Group 1 - The core viewpoint of the articles highlights the performance and valuation of Keri International, which closed at 27.08 yuan with a 3.79% increase, resulting in a rolling PE ratio of 23.95 times and a total market value of 5.33 billion yuan [1] - Keri International operates in the professional services industry, which has an average PE ratio of 54.98 times and a median of 36.23 times, placing Keri International at the 15th position within the industry [1][2] - The company reported a net inflow of 2.36 million yuan in principal funds on June 24, although it experienced a total outflow of 20.71 million yuan over the past five days [1] Group 2 - Keri International specializes in providing comprehensive human resource service solutions, including high-end talent search, recruitment process outsourcing, flexible employment, and technical services [1] - The company has received several awards, including the Best Global Human Resource Service Agency Award for 2024 and recognition as one of the Top 100 Private Enterprises in Beijing [1] - In the latest quarterly report for Q1 2025, Keri International achieved an operating revenue of 3.30 billion yuan, a year-on-year increase of 25.13%, and a net profit of 57.78 million yuan, reflecting a year-on-year growth of 42.15% with a gross profit margin of 5.52% [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.23 yuan on June 24, with a 2.55% increase, resulting in a rolling PE ratio of 40.98 times and a total market value of 2.162 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% with a sales gross margin of 29.26% [2] - The company's PE ratio (TTM) stands at 40.98, while the industry average is 49.12, and the industry median is 36.07 [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the medical device industry average PE at 49.12 and the median at 36.07 [1][2] - The company has received several accolades, including the "Anhui Famous Brand Product" for its "Jingchuan" brand gelatin hollow capsules and recognition as an excellent product brand in the pharmaceutical excipients sector [1]

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. is experiencing a decline in stock price and has a lower PE ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Shandong Pharmaceutical Glass closed at 22.17 yuan, down 1.55%, with a rolling PE ratio of 15.55 times and a total market capitalization of 14.712 billion yuan [1]. - The company operates in the pharmaceutical glass packaging sector, focusing on the research, production, and sales of glass bottles, rubber stoppers, and bottle caps [1]. - The company has been recognized with a new provincial engineering research center and has received the title of "National Manufacturing Single Champion Enterprise," highlighting its leading position in the field [1]. - The "Key Technology and Industrialization of Pharmaceutical Glass Bottle Manufacturing" project won two prestigious industry awards, showcasing its technological innovation and industrial value [1]. Financial Performance - In the first quarter of 2025, the company reported revenue of 1.242 billion yuan, a year-on-year decrease of 1.97%, while net profit was 224 million yuan, a year-on-year increase of 1.29%, with a sales gross margin of 30.21% [1]. Industry Summary - The average PE ratio for the medical device industry is 48.89 times, with a median of 35.79 times, positioning Shandong Pharmaceutical Glass at the 37th rank within the industry [1][2]. - The company has 70,488 shareholders as of March 31, 2025, an increase of 6,223 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1].

Core Viewpoint - The company, Core International, has experienced a decline in stock price and is currently underperforming compared to its industry peers in terms of price-to-earnings ratio (PE) and market capitalization [1][2]. Company Summary - Core International's stock closed at 25.73 yuan, down 5.09%, with a rolling PE of 22.76 times and a total market capitalization of 5.064 billion yuan [1]. - The company operates in the professional services sector, providing comprehensive human resource service solutions, including high-end talent search, recruitment process outsourcing, flexible employment, and technical services [1]. - Recent awards include the 2024 Best Global Human Resource Service Agency and recognition as one of Beijing's top 100 private enterprises [1]. Financial Performance - For Q1 2025, the company reported revenue of 3.303 billion yuan, a year-on-year increase of 25.13%, and a net profit of 57.7839 million yuan, up 42.15%, with a gross profit margin of 5.52% [1]. Industry Comparison - The average PE ratio for the professional services industry is 52.18 times, with a median of 34.96 times, positioning Core International at 14th place within the industry [1][2]. - The industry average market capitalization is 5.516 billion yuan, while the median is 4.448 billion yuan [2].

Group 1 - The core viewpoint of the article highlights the performance and market position of Yara International, noting its current stock price, market capitalization, and financial metrics [1][2] - As of June 19, Yara International's stock closed at 30.62 yuan, down 1.64%, with a rolling PE ratio of 22.57 times and a total market value of 28.294 billion yuan [1] - The average PE ratio for the fertilizer industry is 24.36 times, with a median of 22.14 times, placing Yara International at the 16th position within the industry [1][2] Group 2 - As of the first quarter of 2025, a total of 34 institutions hold shares in Yara International, including 25 funds, 8 other entities, and 1 social security fund, with a total shareholding of 445.682 million shares valued at 10.884 billion yuan [1] - Yara International's main business includes potassium salt mining, potassium fertilizer production, and sales, with primary products being potassium chloride, brine, and others [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 1.213 billion yuan, a year-on-year increase of 91.47%, and a net profit of 384 million yuan, a year-on-year increase of 373.53%, with a gross profit margin of 54.12% [1]

Company Overview - Bohai Leasing's closing price on June 19 was 3.13 yuan, down 1.88%, with a rolling PE ratio of 16.34 times and a total market capitalization of 19.358 billion yuan [1] - The company ranks 9th in the diversified financial industry, which has an average PE ratio of 61.75 times and a median of 26.44 times [1] Shareholder Information - As of March 31, 2025, Bohai Leasing had 133,937 shareholders, a decrease of 13,386 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Business Operations - Bohai Leasing specializes in leasing services and production for aircraft, containers, domestic infrastructure, high-end equipment, commercial properties, and new energy [1] - The main products include aircraft leasing, aircraft sales, container leasing, container sales, operating leasing, financing leasing, and financing leasing consulting [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 17.117 billion yuan, a year-on-year increase of 99.82%, and a net profit of 669 million yuan, up 72.21%, with a gross profit margin of 24.75% [1]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Shandong Pharmaceutical Glass Co., Ltd. (山东药玻), noting its recent stock price increase and low rolling PE ratio compared to the industry average [1][2] - As of June 18, the company's stock closed at 22.42 yuan, up 3.51%, with a rolling PE ratio of 15.73, marking a 50-day low, and a total market capitalization of 14.878 billion yuan [1] - In the medical device industry, the average PE ratio is 49.10, with a median of 36.43, placing Shandong Pharmaceutical Glass at the 37th position in the industry ranking [1][2] Group 2 - The company has 70,488 shareholders as of March 31, 2025, an increase of 6,223 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Shandong Pharmaceutical Glass specializes in the research, production, and sales of various pharmaceutical glass packaging products, including glass bottles, rubber stoppers, and bottle caps [1] - The company has been recognized with a new provincial engineering research center and has received the title of "National Manufacturing Single Champion Enterprise," reflecting its leading position in the field [1] Group 3 - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 1.242 billion yuan, a year-on-year decrease of 1.97%, while net profit was 224 million yuan, a year-on-year increase of 1.29%, with a gross profit margin of 30.21% [1]

Group 1 - The core viewpoint of the news highlights the performance and market position of Leksin Medical, indicating a decline in stock price and a relatively high PE ratio compared to industry averages [1][2] - As of June 18, Leksin Medical's stock closed at 14.19 yuan, down 1.60%, with a rolling PE ratio of 43.68 times and a total market capitalization of 3.086 billion yuan [1] - In the medical device industry, the average PE ratio is 49.10 times, while the median is 36.43 times, placing Leksin Medical at the 87th position in the industry ranking [1][3] Group 2 - Leksin Medical specializes in health IoT and digital health services, with key products including smart electronic blood pressure monitors, health scales, blood glucose monitoring devices, and ECG monitoring equipment [2] - The company is recognized as a national high-tech enterprise and has established several engineering technology research centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - In the latest quarterly report for Q1 2025, Leksin Medical achieved a revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, up 67.88%, with a gross profit margin of 37.38% [2]

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock closed at 229.3 yuan, down 1.17%, with a rolling PE ratio of 24.96 times and a total market capitalization of 278.01 billion yuan [1] - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, positioning Mindray Medical at the 57th rank within the industry [1] - As of March 31, 2025, Mindray Medical had 92,191 shareholders, an increase of 9,446 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] - The PE ratios for Mindray Medical compared to industry averages show a significant disparity, with the industry average PE at 49.10 times and Mindray's at 24.96 times, indicating potential undervaluation [2]

截至2025年一季报，共有29家机构持仓重庆银行，其中基金24家、其他5家，合计持股数120308.27万 股，持股市值116.82亿元。 6月17日，重庆银行今日收盘11.04元，下跌1.43%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到7.38倍，总市值383.59亿元。 从行业市盈率排名来看，公司所处的银行行业市盈率平均6.82倍，行业中值6.56倍，重庆银行排名第36 位。 作者：行情君 本文源自：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)13重庆银行7.387.500.72383.59亿行业平均 6.826.800.713442.48亿行业中值6.566.540.64948.35亿1贵阳银行4.404.310.36222.66亿2华夏银行 4.714.570.411263.65亿3长沙银行5.095.140.59402.56亿4平安银行5.235.130.522282.14亿5北京银行 5.495.450.511408.12亿6江阴银行5.735.750.62117.16亿7光大银行5.765.770.502404.78亿8张家港行 5.925.970.6211 ...